MIR298

Summary

MIR298 (microRNA 298, HGNC:33634) is a microRNA gene on chromosome 20q13.32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100126296 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33634
Approved symbol	MIR298
Name	microRNA 298
Location	20q13.32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-298
Ensembl gene	ENSG00000216031
Ensembl biotype	miRNA
OMIM	614914
Entrez	100126296
RNAcentral	URS000069C337 — miRNA, 88 nt, 3 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000401212

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000401212 — 1 exons

Exon	Start	End
ENSE00001546556	58818226	58818313

Expression profiles

Bgee: expression breadth broad, 77 present calls, max score 84.66.

Top tissues by expression

77 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue	UBERON:0001134	84.66	gold quality
placenta	UBERON:0001987	82.08	gold quality
muscle of leg	UBERON:0001383	80.32	gold quality
urinary bladder	UBERON:0001255	80.12	gold quality
monocyte	CL:0000576	78.03	gold quality
gastrocnemius	UBERON:0001388	77.67	gold quality
islet of Langerhans	UBERON:0000006	75.87	gold quality
adrenal tissue	UBERON:0018303	75.27	gold quality
blood	UBERON:0000178	73.93	gold quality
stomach	UBERON:0000945	73.10	gold quality
calcaneal tendon	UBERON:0003701	72.17	gold quality
right atrium auricular region	UBERON:0006631	71.50	gold quality
adult mammalian kidney	UBERON:0000082	71.47	gold quality
fundus of stomach	UBERON:0001160	71.13	gold quality
body of pancreas	UBERON:0001150	70.43	gold quality
liver	UBERON:0002107	70.29	gold quality
body of stomach	UBERON:0001161	70.10	gold quality
heart	UBERON:0000948	70.00	gold quality
left coronary artery	UBERON:0001626	69.95	gold quality
amygdala	UBERON:0001876	69.05	gold quality
heart left ventricle	UBERON:0002084	68.92	gold quality
endometrium	UBERON:0001295	68.81	gold quality
granulocyte	CL:0000094	68.58	gold quality
thoracic aorta	UBERON:0001515	68.58	gold quality
ascending aorta	UBERON:0001496	68.55	gold quality
right lobe of thyroid gland	UBERON:0001119	68.45	gold quality
anterior cingulate cortex	UBERON:0009835	68.05	gold quality
left adrenal gland	UBERON:0001234	68.02	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.98	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.18

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 11)

• Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. (PMID:22521303)
• The study demonstrates that miR-298 and miR-491-3p downregulates UGT1A expression. (PMID:29172698)
• LINC01287 exerted as a ceRNA and negatively regulated miR-298 expression. MYB was identified as a downstream target of miR-298. The miR-298/MYB axis mediated LINC01287’s effect on hepatocellular carcinoma (HCC) (PMID:30133116)
• Long non-coding RNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. (PMID:30394665)
• Data showed that overexpression of UCA1 significantly decreased the abundance of miR-298 in in adrenocortical cancer (ACC) cells. UCA1 bound miR-298 and negatively regulated the expression of miR-298 in ACC cells. Further data identified that miR-298 bound the 3’-UTR of CDK6 and inhibited the expression of CDK6. (PMID:30935924)
• miR-298 plays a pivotal role in colon cancer invasiveness by targeting PTEN. (PMID:31621072)
• MicroRNA-298 reduces levels of human amyloid-beta precursor protein (APP), beta-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. (PMID:31942037)
• Downregulated circular RNA hsa_circ_0005797 inhibits endometrial cancer by modulating microRNA-298/Catenin delta 1 signaling. (PMID:34852711)
• circFAT1(e2) Inhibits Cell Apoptosis and Facilitates Progression in Vascular Smooth Muscle Cells through miR-298/MYB Axis. (PMID:34938350)
• Effects of microRNA-298 on APP and BACE1 translation differ according to cell type and 3’-UTR variation. (PMID:35197498)
• MiR-298 suppresses the malignant progression of osteosarcoma by targeting JMJD6. (PMID:35442509)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.